FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Penn State women’s volleyball coach Katie Schumacher-Cawley will receive the Jimmy V Award for Perseverance at Wednesday’s ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

Cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to ...